bortezomib: profile and news

Nereus' anticancer drug begins human testing 16 May 2006
The compound is a potent inhibitor of human proteasomes, a high interest drug target for pharmaceutical companies after bortezomib (sold as Velcade by ... - Pharmaceutical Business Review

Velcade Receives Approval For Second-line Use In Multiple Myeloma ... May 10, 2006
...necessary, dose modification. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. In clinical ... - Medical News Today (press release),

Cytogen Reports First Quarter 2006 Financial Results May 8, 2006
..."Our Phase I dose-finding VELSAM trial for QUADRAMET in combination with bortezomib is ahead of schedule, and we expect this trial to conclude by mid- 2006 ... - Yahoo! News (press release)

New drug gives hope to Ulster cancer sufferers Apr 26, 2006
It follows a decision by the Regional Medical Specialities Consortium (RMSC) to license the drug Bortezomib or Velcade for those with myeloma, a cancer of the ... - Therapeutics Daily (subscription) (press release),

Millennium and Johnson & Johnson Pharmaceutical Research and ... Apr 18, 2006
...one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should ... - Yahoo! News (press release)

Baird 2006 Growth Stock Conference to Webcast Millennium ... May 4, 2006
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer ... - PharmaLive.com (press release),

Millennium Achieves First Quarter 2006 Non-GAAP Profitability and ... Apr 27, 2006
...-- VELCADE(R) (bortezomib) for Injection US net product sales up ... VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. ... - PR Newswire (press release),

(PRN) - Youngest Hurricane Victims Facing a Second Crisis - Little ... Apr 18, 2006
...(PRN) - Millennium and Johnson & Johnson Pharmaceutical Research and Development Initiate Phase III Clinical Trial with VELCADE(R) (bortezomib) for Injection ... - Bolsamania.com,

Velcade enters end-stage lymphoma trial Apr 19, 2006
This study builds on clinical data observed in previous trials of Velcade (bortezomib) that showed high objective response rates and a favorable safety profile ... - Pharmaceutical Business Review

Morgan Stanley Global Healthcare Unplugged Conference to Webcast ... Apr 28, 2006
About Millennium Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection ... - PR Newswire (press release),

CuraGen Reports First Quarter 2006 Financial Results Apr 27, 2006
...the treatment of cancer -- Initiated a Phase Ib/II clinical trial evaluating the safety and efficacy of PXD101 in combination with Velcade (bortezomib) for the ... - PR Newswire (press release),